Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER May Form New Office Of Drug Evaluation For CBER Reviewers

Executive Summary

The Center for Drug Evaluation & Research is considering creating a sixth Office of Drug Evaluation to incorporate the CBER review divisions that are transferring to the drug center
Advertisement

Related Content

FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation
FDA Nominee Is Crawford: Choice Emphasizes Continuity, Cooperation
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER/CDER Transition Begins In June: Application Assignments “99.99%” Set
CBER “Best Practices” Must Be Preserved In Reorg, Mass Bio Tells McClellan
BIO Regulatory Affairs VP Woollett Brings CDER Experience From PhRMA
BIO Seeking Regulatory Affairs Head, Gets Friendly Face In House Committee
CBER Director Zoon To Leave FDA In Mid-January To Return To NIH
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
Advertisement
UsernamePublicRestriction

Register

PS041116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel